Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00104520 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: AZLI 75 mg two times a day (BID)/three times a day (TID)
DRUG: Placebo two times a day (BID)/three times a day (TID)

Sponsor

Gilead Sciences